312 related articles for article (PubMed ID: 28892044)
1. A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo.
Comiskey DF; Jacob AG; Sanford BL; Montes M; Goodwin AK; Steiner H; Matsa E; Tapia-Santos AS; Bebee TW; Grieves J; La Perle K; Boyaka P; Chandler DS
Oncogene; 2018 Jan; 37(1):95-106. PubMed ID: 28892044
[TBL] [Abstract][Full Text] [Related]
2. Stress-induced isoforms of MDM2 and MDM4 correlate with high-grade disease and an altered splicing network in pediatric rhabdomyosarcoma.
Jacob AG; O'Brien D; Singh RK; Comiskey DF; Littleton RM; Mohammad F; Gladman JT; Widmann MC; Jeyaraj SC; Bolinger C; Anderson JR; Barkauskas DA; Boris-Lawrie K; Chandler DS
Neoplasia; 2013 Sep; 15(9):1049-63. PubMed ID: 24027430
[TBL] [Abstract][Full Text] [Related]
3. Stress-induced alternative splice forms of MDM2 and MDMX modulate the p53-pathway in distinct ways.
Jacob AG; Singh RK; Comiskey DF; Rouhier MF; Mohammad F; Bebee TW; Chandler DS
PLoS One; 2014; 9(8):e104444. PubMed ID: 25105592
[TBL] [Abstract][Full Text] [Related]
4. SRSF2 Regulation of
Comiskey DF; Montes M; Khurshid S; Singh RK; Chandler DS
Mol Cancer Res; 2020 Feb; 18(2):194-203. PubMed ID: 31662450
[No Abstract] [Full Text] [Related]
5. The MDM2-a splice variant of MDM2 alters transformation in vitro and the tumor spectrum in both Arf- and p53-null models of tumorigenesis.
Volk EL; Fan L; Schuster K; Rehg JE; Harris LC
Mol Cancer Res; 2009 Jun; 7(6):863-9. PubMed ID: 19491200
[TBL] [Abstract][Full Text] [Related]
6. Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines.
Bartel F; Taylor AC; Taubert H; Harris LC
Oncol Res; 2001; 12(11-12):451-7. PubMed ID: 11939408
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-340 inhibits prostate cancer cell proliferation and metastasis by targeting the MDM2-p53 pathway.
Huang K; Tang Y; He L; Dai Y
Oncol Rep; 2016 Feb; 35(2):887-95. PubMed ID: 26718483
[TBL] [Abstract][Full Text] [Related]
8. Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.
Inoue K; Fry EA
Int J Cancer; 2016 Jul; 139(1):33-41. PubMed ID: 26802432
[TBL] [Abstract][Full Text] [Related]
9. The in vivo role of the RP-Mdm2-p53 pathway in signaling oncogenic stress induced by pRb inactivation and Ras overexpression.
Pan W; Issaq S; Zhang Y
PLoS One; 2011; 6(6):e21625. PubMed ID: 21747916
[TBL] [Abstract][Full Text] [Related]
10. Disruption of the RP-MDM2-p53 pathway accelerates APC loss-induced colorectal tumorigenesis.
Liu S; Tackmann NR; Yang J; Zhang Y
Oncogene; 2017 Mar; 36(10):1374-1383. PubMed ID: 27617574
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
Meng X; Carlson NR; Dong J; Zhang Y
Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
[TBL] [Abstract][Full Text] [Related]
12. Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.
Fernandez K; Serinagaoglu Y; Hammond S; Martin LT; Martin PT
Am J Pathol; 2010 Jan; 176(1):416-34. PubMed ID: 20019182
[TBL] [Abstract][Full Text] [Related]
13. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.
Ye J; Liang R; Bai T; Lin Y; Mai R; Wei M; Ye X; Li L; Wu F
J Exp Clin Cancer Res; 2018 Sep; 37(1):212. PubMed ID: 30176896
[TBL] [Abstract][Full Text] [Related]
14. Regulation of hdm2 by stress-induced hdm2alt1 in tumor and nontumorigenic cell lines correlating with p53 stability.
Dias CS; Liu Y; Yau A; Westrick L; Evans SC
Cancer Res; 2006 Oct; 66(19):9467-73. PubMed ID: 17018602
[TBL] [Abstract][Full Text] [Related]
15. Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction.
Fortunato O; Boeri M; Moro M; Verri C; Mensah M; Conte D; Caleca L; Roz L; Pastorino U; Sozzi G
Cell Death Dis; 2014 Dec; 5(12):e1564. PubMed ID: 25501825
[TBL] [Abstract][Full Text] [Related]
16. The regulation of MDM2 oncogene and its impact on human cancers.
Zhao Y; Yu H; Hu W
Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):180-9. PubMed ID: 24389645
[TBL] [Abstract][Full Text] [Related]
17. An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis.
Steinman HA; Burstein E; Lengner C; Gosselin J; Pihan G; Duckett CS; Jones SN
J Biol Chem; 2004 Feb; 279(6):4877-86. PubMed ID: 14612455
[TBL] [Abstract][Full Text] [Related]
18. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
19. Conserved sequences in the final intron of MDM2 are essential for the regulation of alternative splicing of MDM2 in response to stress.
Singh RK; Tapia-Santos A; Bebee TW; Chandler DS
Exp Cell Res; 2009 Nov; 315(19):3419-32. PubMed ID: 19631207
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylation of the Mdm2 oncoprotein by the c-Abl tyrosine kinase regulates p53 tumor suppression and the radiosensitivity of mice.
Carr MI; Roderick JE; Zhang H; Woda BA; Kelliher MA; Jones SN
Proc Natl Acad Sci U S A; 2016 Dec; 113(52):15024-15029. PubMed ID: 27956626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
